Y-mAbs Therapeutics (NASDAQ:YMAB) Announces Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Y-mAbs Therapeutics (NASDAQ:YMAB) posted its quarterly earnings data on Tuesday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02), Zacks reports. The firm had revenue of $26.50 million for the quarter, compared to analyst estimates of $26.70 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same period in the prior year, the company posted ($0.02) EPS. Y-mAbs Therapeutics updated its Q1 2025 guidance to EPS and its FY 2025 guidance to EPS.

Y-mAbs Therapeutics Stock Performance

Shares of NASDAQ YMAB opened at $4.85 on Thursday. Y-mAbs Therapeutics has a 52-week low of $4.25 and a 52-week high of $18.19. The stock has a market cap of $217.23 million, a P/E ratio of -8.98 and a beta of 0.65. The firm has a 50 day moving average price of $6.46 and a 200 day moving average price of $10.62.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on YMAB shares. Bank of America dropped their target price on Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating for the company in a research report on Wednesday. Morgan Stanley dropped their price objective on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating for the company in a report on Wednesday. Truist Financial reduced their target price on shares of Y-mAbs Therapeutics from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday. Wedbush reissued an “outperform” rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Monday. Finally, Brookline Capital Management began coverage on shares of Y-mAbs Therapeutics in a report on Thursday, December 5th. They issued a “buy” rating and a $17.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $19.30.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.